collins_genomicsNature2003

The success of imatinib mesylate gleevec an inhibitor

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: Challenge I-2) should contribute even more fundamentally to therapeutic design. The information needed to determine the therapeutic potential of a gene generally overlaps heavily with the information that reveals its function. The success of imatinib mesylate (Gleevec), an inhibitor of the BCRABL tyrosine kinase, in treating chronic myelogenous leukaemia relied on a detailed molecular understanding of the disease’s genetic cause35. This example offers promise that therapies based on genomic informa- BOX 6 Education M ark e d h e a lt h im pro v e m e nt s fro m in t e gr a t in g g e n o m i c s in t o in d iv i d u a l a n d p u b li c h e a l t h c a re d e p e n d o n t h e e ff e c t i v e e d u c a t i o n o f h e a l t h pro f e s sio n a ls a n d t h e p u b li c a b o ut t h e int erp l a y o f g e n e ti c a n d e n viro n m e nt a l f a c t ors in h e a lt h a n d d is e a s e . H e a lt h pro f e s sio n a ls m u st b e k n o wle d g e a b le a b o ut g e n o mic s t o us e th e o ut c o m e s o f g e n o m i c s re s e arc h e ff e c tiv e ly. T h e p u b li c m u s t b e k n o w l e d g e a b l e t o m a...
View Full Document

Ask a homework question - tutors are online